Expanded Access to L-MTP-PE for the Treatment of Osteosarcoma

Share
Print

Full Title

Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

Purpose

This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients much have osteosarcoma which has been entirely surgically removed or is in complete remission.
  • This study is for patients of all ages.

For more information about this study and to inquire about eligibility, please contact Dr. Emily Slotkin at 212-639-8856.

Protocol

20-324

Investigator

Co-Investigators